-- 
China Lumena, Foxconn, ICBC, Shenhua: Hong Kong Equities Preview

-- B y   K a n a   N i s h i z a w a
-- 
2011-07-22T00:55:34Z

-- http://www.bloomberg.com/news/2011-07-22/china-lumena-foxconn-icbc-shenhua-hong-kong-equities-preview.html
The following companies may have
significant price changes in Hong Kong trading. Stock symbols
are in parentheses. Share prices are as of the last close.  The  Hang Seng Index (HSI)  fell 0.1 percent to 21,987.29. The Hang
Seng  China  Enterprises Index, which tracks so-called H shares of
Chinese companies, declined 0.5 percent to 12,322.25.  China Lumena New Materials Corp. (67 HK): The mineral
producer said Chairman Suolang Duoji’s effective stake fell to
33.2 percent from 63.3 percent. The stock gained 4 percent to
HK$2.60.  China Shenhua Energy Co. (1088 HK): China’s largest coal
miner by market value said its commercial coal production in
June rose 40 percent from a year earlier to 24.8 million tons.
The stock rose 0.5 percent to HK$38.80.  Foxconn International Holdings Ltd. (2038)  (2038 HK): The phone
unit of the world’s biggest contract maker of electronics said
it expects first-half net loss to narrow “significantly” from
a year earlier on smaller impairment charges and wider gross
profit margins. The stock gained 2.8 percent to HK$3.62.  Guotai Junan International Holdings Ltd. (1788)  (1788 HK): The
brokerage expects first-half profit to increase
“significantly” from a year earlier from growth of margin and
other financing business. The stock declined 1 percent to
HK$2.91.  Industrial & Commercial Bank of China (601398)  Ltd. (1398 HK):
China’s biggest bank by market value expects full-year net
income to rise by 21 percent to more than 200 billion yuan ($31
billion), Shanghai Daily reported. An unidentified spokesman for
the company said the report was “misinformation,” the Hong
Kong Economic Journal reported today. The stock was unchanged at
HK$5.71.  Shanghai Pharmaceuticals Holding Co. (2607 HK): T. Rowe
Price Associates, Inc., a U.S.-based investment management firm,
bought 2.3 million H-shares of the Chinese pharmaceuticals maker
at an average price of HK$18.898 each on July 19, according to a
disclosure statement to the Hong Kong stock exchange. The stock
declined 0.3 percent to HK$18.96.  To contact the reporter on this story:
Kana Nishizawa in  Tokyo  at 
 knishizawa5@bloomberg.net .  To contact the editor responsible for this story:
Nick Gentle at 
 ngentle2@bloomberg.net . 